Idorsia - SynapCell Collaboration

We are thrilled to share the promising results of a recent study on Epilepsy conducted by Idorsia, where SynapCell played a key role in assessing efficacy through preclinical EEG testing.  Our collaboration has yielded valuable insights, and we’re proud to have contributed to the advancement of epilepsy research.

This study has just been published in “Antiseizure potential of the triple T-type calcium channel blocker ACT-709478 (apinocaltamide) in rodent models”, Kessler et al. 2025.

As part of a comprehensive set of well-established Epilepsy models, the antiseizure effects of Idorsia’s molecule Apinocaltamide were evaluated in the Genetic Absence Epilepsy Rats from Strasbourg (GAERS*), using in vivo EEG tests in freely moving animals.

The results demonstrated that Apinocaltamide is effective across several epilepsy models, both as a monotherapy and in combination with valproate. Notably, in the GAERS model, Apinocaltamide significantly reduced seizure activity in a dose-dependent manner. Given the GAERS model’s strong predictive validity for absence epilepsy, these findings position Apinocaltamide as a promising therapy for this challenging condition.